Quarterly ResultMay 12, 2026, 04:24 PM
Atea Pharmaceuticals Q1 Net Loss $(45.4)M; HCV Trials on Track
AI Summary
Atea Pharmaceuticals reported a net loss of $(45.4) million, or $(0.57) per share, for Q1 2026, compared to a net loss of $(34.3) million, or $(0.40) per share, in Q1 2025. Research and development expenses increased to $41.1 million. The company provided positive business updates, with its C-BEYOND Phase 3 HCV trial on track for mid-2026 topline results and C-FORWARD enrollment expected to complete mid-2026. Additionally, Atea plans to initiate a Phase 1 trial for its potential first-in-class Hepatitis E Virus candidate, AT-587, in mid-2026.
Key Highlights
- Net loss for Q1 2026 was $(45.4) million, up from $(34.3) million in Q1 2025.
- Diluted net loss per share was $(0.57) in Q1 2026, compared to $(0.40) in Q1 2025.
- Research and development expenses increased to $41.1 million in Q1 2026 from $29.6 million in Q1 2025.
- Cash, cash equivalents, and marketable securities were $256.0 million as of March 31, 2026.
- C-BEYOND Phase 3 HCV trial topline results expected mid-2026; enrollment completed with over 880 patients.
- C-FORWARD Phase 3 HCV trial enrollment on track for mid-2026 completion; results expected year-end 2026.
- Phase 1 initiation for AT-587 (HEV program) expected mid-2026 following encouraging preclinical data.